Immune checkpoint inhibitor-associated hypothyroidism, macular rash and adrenal insufficiency: case report and review of the literature

Abstract Background Immune checkpoint inhibitors (ICIs) represent the most significant therapeutic advancement in oncology over the past decade, with sintilimab demonstrating efficacy as a programmed cell death-1 (PD-1) inhibitor. While these agents have markedly improved tumor response rates and ov...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Zhong-qing Mou, Feng-shou Yi, Xing-ping Wu, Peng Wang, Sheng-li Wu, Li-xin Guo
Formato:	Artigo
Idioma:	Inglês
Publicado em:	BMC 2025-11-01
coleção:	BMC Endocrine Disorders
Assuntos:	Immune checkpoint inhibitors Hypothyroidism Macular rash Adrenal insufficiency Adrenal crisis
Acesso em linha:	https://doi.org/10.1186/s12902-025-02089-7
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!